Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|November 6, 2015
EMA Releases Post-Authorization Efficacy Study Guideline
Author(s)Pharmaceutical Technology Editors
The European agency presents guidelines for conducting post-authorization efficacy studies.
Advertisement
The European Medicines Agency (EMA) has released a draft guideline on how companies should design post-authorization efficacy studies (PAES), which help the European Union to make regulatory decisions. The guideline also describes regulatory aspects for PAES fulfillment. PAES are either required by regulators or conducted voluntarily by drug companies. The guideline applies to both imposed and voluntary PAES and was developed in collaboration with EU Member States.
According to an EMA press release, PAES collect data on the benefits for a particular drug indication after market authorization. These data can include information on how the drug is used in everyday medical practice, how it is used in specific populations, how it relates to the use of other drugs, how it performs over time, and the drug’s mechanism of action. Data results may contribute to changes in labeling or may result in better use of the product.
Comments on the guideline are being accepted by EMA until Jan. 31, 2016.
Source:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement